Get the Stockscreener App
1.55
2.52%
-0.04
After Hours:
1.55
Aldeyra Therapeutics Inc stock is traded at $1.55, with a volume of 466.73K.
It is down -2.52% in the last 24 hours and down -8.82% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$1.59
Open:
$1.57
24h Volume:
466.73K
Relative Volume:
0.16
Market Cap:
$93.50M
Revenue:
-
Net Income/Loss:
$-33.85M
P/E Ratio:
-2.7492
EPS:
-0.5638
Net Cash Flow:
$-33.35M
1W Performance:
-7.74%
1M Performance:
-8.82%
6M Performance:
-68.75%
1Y Performance:
-31.11%
1-Day Range:
$1.53
$1.615
1-Week Range:
$1.505
$1.69
52-Week Range:
$1.07
$6.175
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.55 | 95.91M | 0 | -33.85M | -33.35M | -0.5638 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
ALDX FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. ... - Caledonian Record
ALDX FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, - GlobeNewswire
ALDX Deadline: ALDX Investors with Losses in Excess of $100K Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
Aldeyra Therapeutics, Inc.Common Stock (NQ: ALDX - The Chronicle-Journal
ALDX Shareholders Have Opportunity to Lead Aldeyra Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
ALDX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - Sahm
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming DeadlinesALDX - PR Newswire
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsu - GuruFocus
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Submitted Incomplete Disclosures: SueWallSt - PR Newswire
Is Aldeyra Therapeutics on the Brink of a Breakthrough with Reproxalap - Kavout
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Robbins LLP Reminds ALDX Investors of the Pending Class - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Aldeyra’s Experimental Drug Shows Promising Results In Mid-Stage Alcohol Hepatitis Trial - MSN
ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. - GuruFocus
ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - Charleston Gazette-Mail
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Babcock & Wilcox Enterprises, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud - GlobeNewswire
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ALDX News | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra - GlobeNewswire
ALDX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ALDX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Perceptive (ALDX) amendment shows 0% ownership; Joseph Edelman signs - Stock Titan
Pomerantz LLP Reminds Shareholders: Securities Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. – ALDX - ACCESS Newswire
ALDX Deadline Alert: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - The Daily Tribune News
ALDX SEC FilingsAldeyra Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ALDX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - ChartMill
ALDX Stockholders Have Opportunity to Lead Aldeyra Therapeutics - The National Law Review
ALDX DEADLINE NOTICE: Aldeyra Therapeutics, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 29, 2026 - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX - ChartMill
About Us - FinancialContent
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, - GuruFocus
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra - GlobeNewswire
ALDX Stockholders Have Opportunity to Lead Aldeyra Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
ALDX SHAREHOLDER RIGHTS ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - TMX Newsfile
symbol__ Stock Quote Price and Forecast - CNN
MSN Money - MSN
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - TMX Newsfile
H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Hold Rating, Maintains Target Price $2 - Moomoo
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - ChartMill
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - Carroll County Mirror-Democrat
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to ... - Black Hills Pioneer
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):